<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3700">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03058744</url>
  </required_header>
  <id_info>
    <org_study_id>V01-118A-501</org_study_id>
    <nct_id>NCT03058744</nct_id>
  </id_info>
  <brief_title>Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis</brief_title>
  <official_title>A Phase 1b Open Label, Randomized Study Evaluating the Absorption and Systemic Pharmacokinetics and HPA Axis Suppression Potential of Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valeant Pharmaceuticals International, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valeant Pharmaceuticals International, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Suppression Potential of Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects
      with Moderate to Severe Plaque Psoriasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 1b Open-Label, Randomized Study Evaluating the Absorption and Systemic
      Pharmacokinetics and HPA Axis Suppression Potential of Topically Applied IDP-118 Lotion and
      HP Monad Lotion in Subjects with Moderate to Severe Plaque Psoriasis.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local Skin Reactions (LSRs)</measure>
    <time_frame>8 Weeks</time_frame>
    <description>Tolerability will be evaluated through assessment of local signs and symptoms (itching, dryness, burning/stinging) on a scale of non, mild, moderate, and severe.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>IDP-118 Lotion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 Weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HP Monad Lotion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 Weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ultravate Cream</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 Weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tazorac Cream</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 Weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDP-118 Lotion</intervention_name>
    <description>Lotion</description>
    <arm_group_label>IDP-118 Lotion</arm_group_label>
    <other_name>Lotion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HP Monad Lotion</intervention_name>
    <description>Lotion</description>
    <arm_group_label>HP Monad Lotion</arm_group_label>
    <other_name>Lotion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ultravate Cream</intervention_name>
    <description>Cream</description>
    <arm_group_label>Ultravate Cream</arm_group_label>
    <other_name>Ultravate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tazorac Cream</intervention_name>
    <description>Cream</description>
    <arm_group_label>Tazorac Cream</arm_group_label>
    <other_name>Taz</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or Female of any race, at least 18 years old of age (inclusive)

          -  Freely provides both written and oral informed consent.

          -  Has a clinical diagnosis of psoriasis at the Baseline visit with an Investigator's
             Global Assessment Score of 3 or 4. The face, scalp ,axillae, and intertriginous areas
             are to be excluded in this calculation.

          -  Has an area of plaque psoriasis for topical treatment that involves a BSA of at least
             20%.

          -  The willing and able to avoid prolonged exposure of the treatment area to ultraviolet
             radiation (natural and artificial) for the duration of the study.

        Key Exclusion Criteria:

          -  Has spontaneously improving or rapidly deteriorating plaque psoriasis or postural
             psoriasis, as determined by the investigator.

          -  Presents with psoriasis that was treated with prescription medication and failed to
             respond to presents).

          -  Has a history of adrenal disease.

          -  Presents with any other concurrent skin conditions that could interfere with the
             evaluation of the treatment areas, as determined by the investigator.

          -  Is pregnant, nursing, or planning pregnancy during the study period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Binu J Alexander, MD</last_name>
    <role>Study Director</role>
    <affiliation>Valeant Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Valeant Site 12</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 05</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 01</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 07</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 10</name>
      <address>
        <city>Orange Park</city>
        <state>Florida</state>
        <zip>32065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 09</name>
      <address>
        <city>Sanford</city>
        <state>Florida</state>
        <zip>32771</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 08</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 04</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 06</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 11</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 03</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>73301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 02</name>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <zip>77449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 16, 2017</lastchanged_date>
  <firstreceived_date>December 21, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tazarotene</mesh_term>
    <mesh_term>Halobetasol</mesh_term>
    <mesh_term>Clobetasol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
